Symptom resolution with MMX® mesalazine in patients with mild-to-moderately active ulcerative colitis who are newly diagnosed or have been living with their disease for a prolonge…

Introduction: Ulcerative colitis, (UC) causes patients a number of disruptive and distressing symptoms. While treatment should aim to resolve the underlying source of the disease, in the short term, symptom resolution is an important goal for patients. Objectives: Here, we examine the efficacy of MMX® mesalazine (Mezavant®, Shire Pharmaceuticals Inc, USA; MMX; Cosmo Technologies Ltd, Ireland) for resolving increased stool frequency (SF) and rectal bleeding (RB) in patients with mild-to-moderately active UC who were recently diagnosed or have a longer history of UC. Methods: Data from two, randomised, 8-week, pha…